Burning Rock Biotech Ltd (BNR) stock
BNRNasdaqServices-Medical Laboratories
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 28, 2026Score 4/30
$13.07+0.57 (+4.56%)
Close on Nov 18, 2026Market cap $142.28MP/E –Yield –
Burning Rock Biotech r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was CN¥166.49M, down 28.3% from the year before. The highest annual figure on record is CN¥421.87M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | CN¥166.49M | -28.3% |
| FY2024 | Dec 31, 2024 | CN¥232.29M | -33.1% |
| FY2023 | Dec 31, 2023 | CN¥347.02M | -17.7% |
| FY2022 | Dec 31, 2022 | CN¥421.87M | +14.7% |
| FY2021 | Dec 31, 2021 | CN¥367.86M | +39.4% |
| FY2020 | Dec 31, 2020 | CN¥263.94M | +68.2% |
| FY2019 | Dec 31, 2019 | CN¥156.94M | +49.0% |
| FY2018 | Dec 31, 2018 | CN¥105.30M | – |
See a number that looks wrong?